Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -65.05% | 47.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.14% | -3.36% | |||
| Operating Income | -2.14% | 3.36% | |||
| Income Before Tax | -30.28% | 0.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.94% | 0.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.94% | 0.68% | |||
| EBIT | -2.14% | 3.36% | |||
| EBITDA | -2.16% | 3.37% | |||
| EPS Basic | -32.81% | 0.88% | |||
| Normalized Basic EPS | -28.72% | -3.54% | |||
| EPS Diluted | -32.81% | 0.88% | |||
| Normalized Diluted EPS | -28.72% | -3.54% | |||
| Average Basic Shares Outstanding | -0.66% | 0.20% | |||
| Average Diluted Shares Outstanding | -0.66% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||